TNFRSF11A-Related Autosomal Recessive Osteopetrosis (RANK-Deficient ARO)

TNFRSF11A-related autosomal recessive osteopetrosis is a rare genetic bone disease. It happens when a child inherits two faulty copies of the TNFRSF11A gene, which makes a receptor called RANK. RANK sits on the surface of early bone-eating cells (osteoclast precursors). When it receives the normal signal from its partner (RANKL), the cell grows up into a working osteoclast. Osteoclasts remove old bone so new bone can form. If RANK is missing or does not work, osteoclasts do not form or are too few. Old bone is not removed. Bones become very dense but fragile, bone marrow spaces are narrowed, and nerves can be squeezed inside the skull. This form is called autosomal recessive osteopetrosis (ARO) and is often severe in infancy and childhood. In RANK-deficient ARO, bone density is high, fractures can happen easily, anemia and low platelets can develop because the marrow space is small, and problems with vision and hearing can appear from nerve compression. Some patients also have low immunoglobulins (hypogammaglobulinemia), because RANK signaling also affects parts of the immune system. BioMed Central+3PMC+3PMC+3

TNFRSF11A is the gene that makes RANK, a “doorbell” on early bone-eating cells (osteoclast precursors). When this gene has harmful variants on both copies (autosomal recessive), osteoclasts cannot form or work. Bone keeps getting laid down but not removed, so bones look very dense yet are brittle. The crowded bone spaces also squeeze the bone-marrow, nerves (especially the optic nerves), and ear canals, causing anemia, infections, vision/hearing problems, big spleen/liver, and fractures in infancy. This osteoclast-poor ARO subtype is rare but serious. Importantly, unlike RANKL (TNFSF11) deficiency, RANK deficiency can respond to hematopoietic stem-cell transplant (HSCT), which can restore osteoclasts from healthy donor marrow. NCBI+3PMC+3MedlinePlus+3

A key point for families and clinicians: unlike RANKL deficiency, RANK (TNFRSF11A) deficiency can often be helped by hematopoietic stem-cell transplantation (HSCT), because donor blood-forming cells can build working osteoclasts. PMC

---

Other names

• RANK-deficient osteoclast-poor ARO

• TNFRSF11A-related ARO

• Autosomal recessive osteopetrosis-7 (OPTB7)

• Infantile malignant osteopetrosis due to TNFRSF11A

• Osteoclast-poor osteopetrosis with hypogammaglobulinemia (describes a frequent immune feature) NCBI+1

---

Types

1. Classic osteoclast-poor ARO due to TNFRSF11A – very dense bones, few or no osteoclasts, early onset. PMC

2. AR osteopetrosis with hypogammaglobulinemia – same bone findings plus low immunoglobulins and recurrent infections. PubMed

3. TNFRSF11A-associated dysosteosclerosis (allelic condition) – a related but distinct skeletal disorder reported with TNFRSF11A loss; shows platyspondyly and metaphyseal changes; emphasizes that TNFRSF11A mutations can produce a clinical spectrum. Wiley Online Library+2Orpha.net+2

(Doctors also divide osteopetrosis more broadly into autosomal recessive “malignant/infantile” forms and autosomal dominant “adult” forms, but TNFRSF11A disease belongs to the recessive, infantile group.) Frontiers+1

---

Causes

Important note: This disease is genetic. The root cause is biallelic (two-copy) pathogenic variants in TNFRSF11A. The items below explain the different ways that defect shows up and the factors that influence it.

1. Biallelic loss-of-function variants in TNFRSF11A (nonsense, frameshift) that remove or truncate RANK. This blocks osteoclast development. PMC

2. Missense variants that change the RANK extracellular domain, reducing binding to RANKL. Signal does not pass, so precursors fail to mature. PMC

3. Missense or splice variants in the transmembrane/cytoplasmic tail, impairing NF-κB signaling inside the cell. MedlinePlus

4. Promoter or splicing defects that lower RANK amounts below the threshold needed for osteoclastogenesis. PMC

5. Compound heterozygosity (two different harmful variants, one from each parent) leading to severe loss of function. PMC+1

6. Founder mutations in isolated populations, increasing local disease frequency. Frontiers

7. Consanguinity (parents related by blood) raising the chance that a child inherits the same rare variant twice. Frontiers

8. Defective RANK trafficking to the cell surface, so the receptor cannot meet RANKL. PMC

9. Disrupted RANK–TRAF/NF-κB pathway, a key downstream signaling cascade for osteoclast survival and function. MedlinePlus

10. Failure of osteoclast precursor fusion, a step that depends on intact RANK signaling. PMC

11. Early apoptosis (cell death) of osteoclast precursors because survival signals via RANK are lost. PMC

12. Impaired cross-talk with stromal/osteoblast cells that normally present RANKL and support osteoclast maturation. PMC

13. Immune system signaling defects linked to RANK, contributing to hypogammaglobulinemia and infections. PubMed

14. Prenatal onset when severe variants act during fetal skeletal development, causing dense bones at birth. BioMed Central

15. Secondary marrow failure from narrowed marrow spaces, worsening anemia and low platelets. (Downstream effect that drives symptoms.) BioMed Central

16. Cranial base foraminal narrowing from unchecked bone growth, compressing cranial nerves. (Mechanistic driver of vision/hearing loss.) BioMed Central

17. Impaired tooth eruption due to dense alveolar bone blocking normal eruption pathways. BioMed Central

18. Skeletal geometry changes (Erlenmeyer-flask deformity) that reflect disordered remodeling without osteoclast shaping. BioMed Central

19. Progressive “bone-within-bone” appearance from failure to resorb primary spongiosa. BioMed Central

20. Genotype–phenotype variability, where different TNFRSF11A variants produce a range from classic ARO to dysosteosclerosis-like pictures. Frontiers+1

---

Common symptoms and signs

1. Very dense bones but easy fractures – bone looks strong on X-ray but breaks easily because it is not remodeled correctly. BioMed Central

2. Anemia – marrow space is small, so fewer red cells are made; children can look pale and tire easily. BioMed Central

3. Low platelets (thrombocytopenia) – can cause easy bruising or nosebleeds. BioMed Central

4. Frequent infections – partly from reduced marrow function and sometimes low immunoglobulins. PubMed

5. Enlarged liver and spleen (hepatosplenomegaly) – the body tries to make blood cells outside the marrow. PubMed

6. Poor growth or failure to thrive – chronic illness and marrow failure can slow growth. PubMed

7. Big head (macrocephaly) and frontal bossing – skull bones thicken abnormally. PubMed

8. Vision problems – narrowing of skull openings can press on the optic nerves, leading to reduced vision or blindness. BioMed Central

9. Hearing loss – similar pressure on auditory nerves and middle ear changes. PubMed

10. Facial nerve palsy – compression can weaken facial muscles. BioMed Central

11. Dental problems and delayed tooth eruption – dense jaw bone blocks normal tooth paths, raising caries and abscess risks. BioMed Central

12. Bone pain and irritability – from sclerotic bones and marrow pressure. BioMed Central

13. Pathologic fractures with minor trauma – especially in long bones. BioMed Central

14. Developmental delay – may be secondary to chronic illness, poor vision/hearing, or intracranial pressure. BioMed Central

15. Respiratory issues – recurrent chest infections due to immune problems and reduced space in the chest in severe cases. PubMed

---

Diagnostic tests

A) Physical examination (bedside observations)

1. Growth and nutrition check – weight/length curves often fall; helps stage illness severity. BioMed Central

2. Skin and mucosa exam for pallor and bruises – suggests anemia or low platelets from marrow crowding. BioMed Central

3. Head and face inspection – macrocephaly, frontal bossing, and midface changes hint at osteopetrosis. PubMed

4. Cranial nerve screening – simple bedside checks of vision, eye movements, facial movement, hearing, and swallowing can detect nerve compression. BioMed Central

5. Abdomen palpation – liver and spleen size reflects extramedullary hematopoiesis and disease load. PubMed

B) Manual/office tests (simple functional tests without machines or with basic tools)

6. Visual acuity and fundus exam – reduced acuity or optic disc pallor indicate optic nerve compromise. BioMed Central

7. Rinne and Weber tuning-fork tests – quick bedside screens for conductive or sensorineural hearing loss. BioMed Central

8. Dental exam – delayed tooth eruption, enamel defects, and malocclusion are common clues. BioMed Central

9. Neurologic exam of peripheral nerves – facial weakness or altered corneal reflex can reveal nerve entrapment. BioMed Central

10. Fracture risk assessment – history of low-energy fractures and localized bone tenderness guide urgent imaging. BioMed Central

C) Laboratory and pathological tests

11. Complete blood count (CBC) with smear – anemia and thrombocytopenia are common; smear may show leukoerythroblastosis when marrow is packed. BioMed Central

12. Serum immunoglobulins (IgG, IgA, IgM) – can be low in TNFRSF11A disease and correlate with infection risk. PubMed

13. Bone turnover markers – often show low resorption (e.g., TRAP 5b low) and sometimes altered bone formation (ALP). PMC

14. Calcium, phosphate, PTH, vitamin D – usually near normal, helping rule out metabolic bone mimics. BioMed Central

15. Genetic testing for TNFRSF11A (sequence + deletion/duplication) – confirms diagnosis; many labs list OPTB7 panels. NCBI

16. Osteoclast assays in research settings – may show absent osteoclast formation from patient precursors; not needed clinically for most families. PMC

D) Electrodiagnostic tests

17. Visual evoked potentials (VEP) – detect slowed optic pathway conduction from nerve compression before permanent loss. BioMed Central

18. Auditory brainstem response (ABR) – objective test for hearing pathway damage at the nerve/brainstem level. BioMed Central

E) Imaging tests

19. Plain X-rays / skeletal survey – show generalized osteosclerosis, “bone-within-bone”, and Erlenmeyer-flask deformities; cornerstone of diagnosis. BioMed Central

20. CT or MRI of skull base and orbits – reveals narrowed foramina that trap cranial nerves; MRI of spine and long bones shows loss of marrow space. BioMed Central

Non-pharmacological treatments (therapies & “other” care)

1. Early multidisciplinary care. Coordinate pediatrics, hematology, neurology/neurosurgery, ophthalmology, ENT, dentistry, genetics, physio/OT, and transplant teams to monitor marrow failure, cranial-nerve compression, and fractures; timely referrals improve outcomes. OUP Academic+1

2. Fracture prevention & safe handling. Teach caregivers protected lifting, fall-proofing, and avoiding contact sports; brittle, sclerotic bone fractures easily despite “strong-looking” X-rays. PMC

3. Physiotherapy (gentle, low-impact). Maintain joint range, muscle strength, and balance using low-load, supervised exercise to limit deconditioning without provoking fractures. PMC

4. Occupational therapy. Optimize home ergonomics and daily-living aids to reduce fall and compression risks while supporting development. PMC

5. Low-vision services. Because the optic canal often narrows, early low-vision rehab (contrast, lighting, magnification) preserves function while surgical options are considered. OUP Academic

6. Audiology care. Repeated hearing checks and timely amplification if needed; skull sclerosis can impair middle/inner ear function. OUP Academic

7. Dental prevention program. Start fluoride varnish, oral-hygiene coaching, and early caries interception; osteopetrosis raises risk of dental anomalies and jaw osteomyelitis. rareconnect.org

8. Infection vigilance & rapid treatment plans. Crowded marrow predisposes to neutropenia/infections; families need “fever plans” for rapid evaluation. PMC

9. Transfusion support protocols. Where anemia/thrombocytopenia occur, standardized thresholds and irradiated blood products help bridge to definitive therapy. PMC

10. Nutrition by a pediatric dietitian. Balance energy/protein for growth; avoid unnecessary calcium loading; ensure safe vitamin D exposure under medical guidance. rareconnect.org

11. Developmental & educational support. Early intervention for motor/vision/hearing delays can offset secondary disability. OUP Academic

12. Skin integrity & pressure prevention. Limited mobility raises sore risk—rotate positions, use cushions, and monitor bony prominences. PMC

13. Vaccination per schedule. Follow routine immunizations; coordinate timing if HSCT is planned or if interferon gamma is used. FDA Access Data

14. Genetic counseling. Explain autosomal-recessive inheritance, carrier testing, and options for future pregnancies. PMC

15. Headache/neuropathy watch. Teach families to recognize red flags of cranial-nerve compression (vision loss, facial weakness, hearing changes) for urgent review. OUP Academic

16. Bone-safe positioning & bracing. Custom orthoses or soft bracing can reduce pain and deformity progression; avoid rigid devices that increase focal stress. PMC

17. Sun/eye protection. Light sensitivity can worsen with optic-nerve stress; sunglasses/filters help comfort while evaluation continues. OUP Academic

18. Psychosocial support. Chronic rare disease burdens families; counseling and peer support improve adherence and quality of life. PMC

19. Pre-HSCT optimization. Before transplant, correct nutrition, treat infections, and plan central-line care to reduce complications. OUP Academic

20. Post-HSCT hypercalcemia preparedness. After successful HSCT in RANK-ARO, rapid bone resorption can cause significant hypercalcemia—teams need monitoring and protocols. PubMed+1

---

Drug treatments

1. Interferon gamma-1b (Actimmune®).
   Class: cytokine. Use: slows progression in severe malignant osteopetrosis; sometimes a bridge to HSCT. Mechanism: boosts macrophage/osteoclast activity and immune function. Dose/Timing: subcutaneous thrice weekly per label; pediatric dosing individualized. Key risks: fever, cytopenias, liver enzyme rise—monitor CBC/LFTs. (FDA-approved for delaying progression in severe malignant osteopetrosis). FDA Access Data+2FDA Access Data+2

2. Calcitriol (active vitamin D).
   Class: vitamin D analog. Use: historically tested to stimulate osteoclasts in some osteopetrosis; evidence mixed; specialist-only. Mechanism: increases RANKL signaling and osteoclast activation in responsive subtypes. Risks: hypercalcemia—close monitoring required. (Label shows pharmacology; indication for hypocalcemia, not ARO—off-label here.) rareconnect.org

3. Short-course corticosteroids (e.g., prednisolone).
   Class: glucocorticoid. Use: may transiently improve anemia/splenomegaly or nerve edema while arranging definitive care. Mechanism: anti-inflammatory; may modulate marrow environment. Risks: growth suppression, infection risk—limit duration. (Drug facts from FDA labeling; use in ARO is off-label.) rareconnect.org

4. Broad-spectrum antibiotics (for osteomyelitis/cellulitis).
   Class: antibacterial. Use: treat jaw or bone infections, which are more likely with dense, poorly vascular bone. Mechanism: eradicates pathogens; prolonged courses often needed. Risks: C. difficile, resistance—culture-guided therapy preferred. rareconnect.org

5. Antifungals (when indicated).
   Used for proven fungal infections in immunocompromised states pre/post-HSCT; selection guided by cultures and drug–drug interactions with transplant meds. OUP Academic

6. Erythropoiesis-stimulating agents (epoetin alfa).
   Class: ESA. Use: selected cases of symptomatic anemia when transfusions undesirable; transplant plan pending. Mechanism: stimulates RBC production. Risks: hypertension/thrombosis—specialist monitoring. (Label for drug facts; off-label for ARO). PMC

7. Analgesics (acetaminophen first-line).
   Class: non-opioid analgesic. Use: pain from fractures or procedures. Mechanism: central analgesia. Note: avoid routine NSAIDs if bleeding risk or renal concerns; tailor to case. OUP Academic

8. Anticonvulsants (if cranial-nerve compression triggers seizures).
   Used per neurology guidance; treat symptomatically while structural issue is assessed. OUP Academic

9. Antiemetics & supportive HSCT meds.
   During conditioning/transplant, guideline-based antiemetics, antimicrobials, and prophylaxis are used per transplant protocols. OUP Academic

10. Calcium-lowering agents post-HSCT (e.g., IV fluids, loop diuretics, calcitonin, bisphosphonates for short rescue).
    Use: manage post-HSCT rebound hypercalcemia; brief, carefully supervised courses only. ScienceDirect

11. Topical oral antiseptics/antimicrobials.
    Reduce oral bacterial load to prevent jaw infections in high-risk teeth and jaws. rareconnect.org

12. Hematology supportive meds (e.g., folate, B12 if deficient).
    Corrects reversible contributors to cytopenias while planning definitive care. PMC

13. Antivirals (per standard indications).
    For proven or high-risk viral infections in immunocompromised settings around HSCT. OUP Academic

14. Growth factor support (G-CSF) in severe neutropenia (case-by-case).
    Considered selectively in infection-prone patients; transplant center guidance needed. OUP Academic

15. Proton-pump inhibitors (procedure-related stress gastritis prophylaxis).
    Used per ICU/surgical protocols; minimize exposure. OUP Academic

16. Antihypertensives (if steroid/ESA-related).
    Manage treatment-emergent hypertension. PMC

17. Antidiarrheals/rehydration for treatment toxicities.
    Supportive care per pediatric oncology/transplant standards. OUP Academic

18. Antipruritics/antipyretics for interferon-related symptoms.
    Symptom control improves adherence; monitor for cytopenias and LFT changes. FDA Access Data

19. Topical fluoride & high-fluoride toothpaste.
    Reduces caries risk in vulnerable dentition. rareconnect.org

20. Iron chelation (only if transfusion-related iron overload).
    Rarely required in ARO; follow hematology guidance. PMC

Important: Consensus guidelines flag interferon-γ1b as experimental outside infantile malignant cases, and emphasize gene-specific decisions and HSCT planning. OUP Academic

---

Dietary molecular supplements

1. Vitamin D (physiologic doses only). Maintain sufficiency; avoid high dosing unless specialist-directed, because hypercalcemia risk is real. rareconnect.org

2. Calcium (avoid routine high intakes). Use normal age-appropriate intake unless treating deficiency; excess can worsen hypercalcemia, especially post-HSCT. ScienceDirect

3. Protein adequacy (whey/complete proteins as needed). Supports growth and healing without altering bone resorption pathways. PMC

4. Omega-3 fatty acids. General anti-inflammatory support; no disease-specific approval—adjunct only. PMC

5. Folate. Correct deficiency if present to support erythropoiesis. PMC

6. Vitamin B12. Treat deficiency-related anemia; check levels first. PMC

7. Vitamin C (dietary). Supports collagen synthesis for fracture repair; keep within age-appropriate limits. PMC

8. Magnesium (if low). Low Mg can blunt vitamin D/PTH physiology; replete if deficient. PMC

9. Zinc (if low). Supports wound healing and immune function; supplement only with documented deficiency. PMC

10. Multivitamin (age-appropriate). Fills small gaps while avoiding pharmacologic megadoses. PMC

---

Immunity booster / regenerative / stem-cell” medicines

1. HSCT conditioning/engraftment meds (protocol-based). These do not “boost” immunity but enable donor marrow to replace defective osteoclast lineage—the only gene-level restorative option for RANK-ARO. PubMed

2. Interferon gamma-1b. Immune-modulating cytokine with label for malignant osteopetrosis; symptom/hematologic benefits in selected cases. FDA Access Data

3. IVIG (selected immune complications). For hypogammaglobulinemia occasionally reported in RANK-ARO; individualized. ScienceDirect

4. Vaccines (per national schedule). Core for immune protection; schedules may reset post-HSCT per transplant policy. FDA Access Data

5. G-CSF (when severe neutropenia). Short-term support during infections or pre-HSCT as guided by hematology. OUP Academic

6. Clinical-trial agents (future regenerative options). At present, no approved gene therapy for ARO; trials focus on better HSCT and complication control. Frontiers

---

Surgeries (what is done and why)

1. Hematopoietic stem-cell transplantation (HSCT).
   What: donor stem cells infuse after conditioning. Why: replaces defective RANK-negative hematopoietic lineage, allowing normal osteoclast development and reversing the bone disease in many cases. Notes: In RANK-ARO, HSCT has shown near-curative results; watch for post-HSCT hypercalcemia. PubMed+1

2. Optic-canal decompression.
   What: neurosurgical/ENT procedure to enlarge the narrowed optic canal. Why: relieves pressure on the optic nerve to preserve sight in progressive compressive neuropathy. OUP Academic+1

3. Cranial-nerve/foramina decompressions (case-by-case).
   What: targeted bony decompressions for facial or auditory nerve compression. Why: manage debilitating neuropathies when imaging shows severe narrowing. OUP Academic

4. Orthopedic fixation of fractures/deformities.
   What: gentle, well-planned fixation/casting. Why: brittle bone still fractures; skilled pediatric ortho reduces malunion risk. PMC

5. Dental surgery for osteomyelitis or non-erupted teeth.
   What: cautious extractions/debridement with antibiotic coverage. Why: dense, poorly vascular bone raises infection risk in jaws. rareconnect.org

---

Preventions

1. Home fall-proofing and safe baby/child handling routines. PMC

2. Regular dental hygiene + fluoride care to prevent jaw infections. rareconnect.org

3. Prompt fever evaluation and written “infection plan.” PMC

4. Vision/hearing screening every visit in infancy/early childhood. OUP Academic

5. Keep vaccinations up to date; coordinate around transplant plans. FDA Access Data

6. Avoid contact sports or high-impact play; use helmets/guards appropriately. PMC

7. Use car seats and mobility aids exactly as instructed to limit fracture risk. PMC

8. Maintain normal, not excessive, calcium/vitamin D unless prescribed. rareconnect.org

9. Early genetics visit for siblings/future pregnancies. PMC

10. Keep copies of imaging/genetic reports for emergency providers. OUP Academic

---

When to see a doctor

• Sudden vision changes, squinting, or new nystagmus (possible optic-nerve compression). OUP Academic

• New facial weakness, hearing loss, or trouble swallowing (cranial-nerve compression). OUP Academic

• Fever, lethargy, or breathing fast (infection with possible marrow compromise). PMC

• Bone pain after minor bumps, limb deformity, or refusal to bear weight (fracture). PMC

• Excessive thirst, vomiting, constipation after HSCT (may signal hypercalcemia). ScienceDirect

---

Foods: what to eat / what to avoid

Eat (age-appropriate):

• Balanced calories with adequate protein (fish, eggs, legumes) for growth/repair. PMC

• Fruits/vegetables for micronutrients and fiber. PMC

• Whole grains for steady energy to support therapy. PMC

• Hydration (water) to help during fevers or post-HSCT. OUP Academic

• Normal calcium and vitamin D intake unless your specialist prescribes otherwise. rareconnect.org

Avoid (unless prescribed otherwise):

• High-dose calcium/vitamin D supplements without medical advice. rareconnect.org

• Very high sodium ultra-processed foods (fluid/pressure issues). OUP Academic

• Alcohol/energy drinks (older teens/adults) around transplant/meds. OUP Academic

• Raw/undercooked foods during neutropenia/around HSCT (infection risk). OUP Academic

• Contact sports “food for fun” settings (e.g., hard playgrounds) — choose soft-surface play. PMC

---

FAQs

1. Is TNFRSF11A-ARO the same as RANKL deficiency? No. TNFRSF11A affects the receptor (RANK). TNFSF11 affects the ligand (RANKL). This matters for treatment. NCBI

2. Can HSCT cure TNFRSF11A-ARO? It can be highly effective because donor marrow provides osteoclast precursors that can express RANK; published series show near-cure in many children. PubMed

3. Why do some sources say HSCT is “not successful” in RANK/ RANKL ARO? That warning aims mainly at RANKL (TNFSF11) deficiency; gene-specific counseling is essential. NCBI

4. Why is vision at risk? Dense skull narrows the optic canal and compresses the optic nerve; urgent decompression sometimes needed. OUP Academic

5. Why are bones both dense and fragile? Bone is formed but not resorbed, so micro-architecture is abnormal; it cracks instead of flexing. PMC

6. Is interferon-γ1b an approved medicine for osteopetrosis? Yes—FDA approved it to delay progression in severe malignant osteopetrosis; use remains specialized. FDA Access Data

7. Will interferon-γ1b replace HSCT? No; it may stabilize some features, but HSCT is the only restorative option for RANK-ARO. OUP Academic+1

8. Why the concern about hypercalcemia after HSCT? Once normal osteoclasts appear, stored calcium can surge into blood; monitor and treat promptly. ScienceDirect

9. Are “bone-strengthening” drugs (bisphosphonates) used? Generally not to strengthen bone in ARO (osteoclasts already underactive); very short, targeted use may treat post-HSCT hypercalcemia only. ScienceDirect

10. Does diet cure ARO? No. Diet supports growth and recovery but does not fix the genetic osteoclast defect. PMC

11. What age is typical at diagnosis? Most present in infancy with anemia, fractures, or cranial-nerve signs. MedlinePlus

12. Is hearing loss permanent? Risk exists; early screening and decompression or amplification can preserve function. OUP Academic

13. Can adults have RANK-ARO? Survivors can reach adulthood, especially after HSCT; ongoing orthopedic/neurologic care remains important. PubMed

14. What about immunity problems? Some RANK-ARO cases show hypogammaglobulinemia; assess and treat (e.g., IVIG) if clinically significant. ScienceDirect

15. Where can clinicians find formal guidance? See the 2017 international consensus on diagnosis/management and relevant GeneReviews chapters. OUP Academic+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.